Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.

Cancer letters - 10 Jul 2017

Huang Mengxi, Chen Cheng, Geng Jian, Han Dong, Wang Tao, Xie Tao, Wang Liya, Wang Ye, Wang Chunhua, Lei Zengjie, Chu Xiaoyuan

Abstract excerpt

Use of the tyrosine kinase inhibitor sorafenib in patients with advanced hepatocellular carcinoma (HCC) is often hindered by the development of resistance, which has been recently shown to be associated with the emergence of a cancer stem cell (CSC) subpopulation. However, it remains largely unknown whether epigenetic mechanisms, especially histone posttranslational modifications, are causally linked to the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzoates
Share to Cyclopropanes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histone Demethylases

Share to Niacinamide

Share to Phenylurea Compounds

Share to Sorafenib

Share to Tumor Burden

Share to Wnt Signaling Pathway

Source

Identifiers

PMID: 28377178
DOI: 10.1016/j.canlet.2017.03.038

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.PMID 28377178Read ↗

MCM2 promotes the stemness and sorafenib resistance of hepatocellular carcinoma cells via hippo signalingSemantic proximity Read ↗

The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinomaSemantic proximity Read ↗

Dishevelled 1-Regulated Superpotent Cancer Stem Cells Mediate Wnt Heterogeneity and Tumor Progression in Hepatocellular Carcinoma.Semantic proximity Read ↗

Targeted silencing of SOCS1 by DNMT1 promotes stemness of human liver cancer stem-like cellsSemantic proximity Read ↗

Coordinated activation of DNMT3a and TET2 in cancer stem cell-like cells initiates and sustains drug resistance in hepatocellular carcinomaSemantic proximity Read ↗

Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagySemantic proximity Read ↗

Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yes‐Associated Protein 1 Activation and Transient Expansion of Stem‐Like Cancer CellsSemantic proximity Read ↗

Chemotherapy‐Enriched THBS2‐Deficient Cancer Stem Cells Drive Hepatocarcinogenesis through Matrix Softness Induced Histone H3 ModificationsSemantic proximity Read ↗

HDAC11 Regulates Glycolysis through the LKB1/AMPK Signaling Pathway to Maintain Hepatocellular Carcinoma StemnessSemantic proximity Read ↗

DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancerSemantic proximity Read ↗

Epigenetic reprogramming modulates malignant properties of human liver cancerSemantic proximity Read ↗

HBx Facilitates Drug Resistance in Hepatocellular Carcinoma via CD133-regulated Self-renewal of Liver Cancer Stem CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.